Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Obesity is a big driver of healthcare spending in South Africa, yet most medical schemes still limit cover for effective ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

Wegovy® (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic metabolic dysfunction-associated ...

FEELING achy, feverish or wiped out? As ‘superflu’ surges across the country, it might be easy to assume you’ve caught the ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

New research reveals that taking a GLP-1 can be equivalent to '10 years of ageing' on the body, if proper precautions aren't taken ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...